[GKOS]

Mid 2026-10-10 01:17:54

Glaukos' iDose TR meets primary goal in phase 4 trial

Row 2026-10-08 09:13:40

Glaukos CDO Tomas Navratil sells $251,120 in company stock

Row 2026-10-08 04:02:20

Glaukos options flow shows bearish hedge as GKOS rallies 6.6%

Row 2026-09-29 08:04:01

Glaukos chief development officer sells $249k in stock

Mid 2026-07-30 11:02:08

Glaukos outlines $680M-$700M 2026 net sales as iDose TR seen at $275M-$280M